Pixium Vision touts 1st use of Prima bionic vision system

Pixium Vision (EPA:PIX) yesterday announced the first successful trial implantation and activation of its Prima next-generation miniaturized wireless photovoltaic sub-retinal implant, and that the system successfully produced visual perception. With the implantation complete, the patient will begin the re-education phase of the study which includes a six-month and 36-month follow-up, the Paris-based company said. “This first successful activation is a major milestone, validating Prima’s concept in patients with advanced dry AMD. The close collaboration between our team at Stanford University and Pixium Vision has been critical for successful development and testing of Prima. We will continue to advance the photovoltaic implants in our lab, seeking further increases in resolution and in quality of the visual perception,” Prima system inventor Dr. Daniel Palanker of Stanford University said in a press release. Pixium Vision said its study of the device aims to explore the use of the Prima system in eliciting central visual perception in patients with lost sight due to atrophic advanced dry age-related macular degeneration, and looks to recruit up to five patients. Evaluations in the trial are slated for six months and 36 months. The first implantation of the system was performed by principal investigator Dr. Yannick Le Mer at Paris’ Fondation Ophtalmologique Rothschild and Hôpital des Quinze-Vingt, the company said. “This first successful Prima impla...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Optical/Ophthalmic Pixium Vision Source Type: news